Efficacy, safety and prognostic factors of camrelizumab plus carboplatin and pemetrexed chemotherapy in advanced lung adenocarcinoma patients.

Jialing LvWen ZhangRuoyu DengYanqiong ChenMeiyan LiuZhijun ZhangQing WangYongmei HeYaling LiuFengting WangZengbo LvHuahua ZhouChongxin LiTengfei ZhangYanyan FuXingqiang ZhaoQiuping BaoYi MiaoLin WangMeifang HuangChao Zhang

Published in: Journal of clinical pharmacy and therapeutics (2022)

Camrelizumab plus CP chemotherapy achieves favourable efficacy and tolerable adverse events in advanced lung adenocarcinoma patients.

Keyphrases

prognostic factors
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
randomized controlled trial
clinical trial
patient reported outcomes
locally advanced
radiation therapy
rectal cancer
epidermal growth factor receptor